NorthStar inks supply deal with Clarity

By staff writers

February 12, 2020 -- NorthStar Medical Radioisotopes parent NorthStar Medical Technologies has signed a letter of intent to supply radiopharmaceutical firm Clarity Pharmaceuticals with copper-67 (Cu-67).

Under the deal, NorthStar will provide Clarity with the beta-emitting radioisotope as an active pharmaceutical ingredient for the company's pipeline of copper-based radiopharmaceuticals. NorthStar said it will be a major U.S. supplier of Cu-67 for Clarity, which is developing targeting agents for potential treatment of neuroblastoma, prostate, breast, and ovarian cancers.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking